NEW YORK, Oct. 10 - Orchid Biosciences will gradually pull out of the SNP-genotyping business as it moves closer to launching its GeneShield personalized-medicine platform, George Poste, the company's new chairman, said today.
Registering provides access to this and other free content.
Already have an account?Login Now.
In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.
Cancer clinical trial patients settle with Anil Potti and Duke University.
A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.
Two Johns Hopkins researchers discuss the need for evidence-based data analysis.